>90% first time ripening success
Safe and gentle
12 hour dilation
Excellent patient comfort
New clinical data
Based on list prices, Dilapan-S® has been a more cost effective option for the majority of NHS hospitals that have switched to using Dilapan-S® in their inductions. Features that make Dilapan-S® a cost effective option include;
- Reduced repeated rounds of ripening
The SOLVE trial showed Dilapan-S® has a 10% higher 1st round success rate vs. dinoprostone vaginal insert7.
- High efficacy
Vaginal delivery rate is comparable to prostaglandins with higher 1st round success7,8.
- Enhanced safety
The non-pharmacaological mode of action of Dilapan-S® minimises the risk of hyperstimulation with NRFHR, meaning staff spend significantly less time monitoring and administering pain relief. A 2022 study showed staff spend 2.4hours less time per patient per induction vs. dinoprostone vaginal insert9.
- Increased opportunity for outpatient inductions
Dilapan-S®’ favourable safety profile enables more patients to be induced at home. A large Essex maternity unit increased their outpatient inductions from 8% to 39% after introducing Dilapan-S®10. The HOMECARE trial showed using Dilapan-S® for outpatient IOL saves 11% of hospital spending vs. inpatient IOL11.
Watch the midwife-led IOL video below to find out how Dilapan-S® offered savings of £200,000+ p/a for a london maternity unit.